NSE · DHANSA
Dhansa Labs Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹41 Cr with net profit ₹2 Cr — a 5.16% net margin, versus 3.11% the period before.
Shareholding
As of 2026-06-30
- Promoter65.05%
- Public34.95%
1,201 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.98× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pesticides / Agrochemicals - Indian · ranked #26 of 29 by market cap · medians across 26 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| UPL Limited | ₹51,406 Cr | 48.46 | 1.48 | 5.54% | 3.71% |
| PI Industries Ltd. | ₹41,782 Cr | 208.63 | 3.72 | 11.76% | 19.67% |
| Sumitomo Chemical India Ltd. | ₹25,042 Cr | 224.98 | 7.39 | 16.02% | 17.86% |
| Sharda Cropchem Ltd. | ₹7,440 Cr | 23.35 | 2.37 | 21.71% | 12.93% |
| Dhanuka Agritech Ltd. | ₹4,589 Cr | 46.93 | 2.73 | 21.17% | 14.59% |
| NACL Industries Limited | ₹4,571 Cr | — | 6.7 | 2.49% | 81.41% |
| Rallis India Ltd. | ₹4,254 Cr | 28.19 | 2.08 | 9.88% | 7.22% |
| Bhagiradha Chemicals & Industries Ltd. | ₹3,463 Cr | 861.45 | 4.96 | 2.6% | 3.39% |
| Bharat Rasayan Ltd. | ₹2,121 Cr | 55.59 | 1.66 | 11.43% | 11.73% |
| Insecticides India Ltd. | ₹1,831 Cr | 156.5 | 1.5 | 0.11% | 6.51% |
| Dhansa Labs Limited(this company) | ₹46 Cr | 23.25 | 0.47 | 5.59% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashDhansa Labs Limited is listed on the Indian markets with a market capitalization of Rs 52 Cr. The company reported revenue of Rs 133.19 Cr and an EPS of Rs 2.21. Its price-to-earnings ratio is 26.25 and book value is Rs 39.62.
Positives
- +The institutional shareholding has increased from 0% in February 2024 to 0.3271% in May 2026.
- +The debt-to-equity ratio is 0.81, indicating a manageable level of debt.
- +Promoter holding remains substantial at 65.0455% as of May 2026.
- +The company has reported positive EPS of Rs 2.21 for the latest period.
Negatives
- −The net profit has decreased from Rs 7.72 Cr in Mar 2024 to Rs 4.78 Cr in Mar 2025.
- −The company's profit margin is 0%.
- −Promoter holding has decreased from 70.1469% in Mar 2025 to 65.0455% in May 2026.
- −The Return on Equity is 5.59% and Return on Capital Employed is 7.23%, indicating low efficiency in generating returns.
- −The company is under ESM 1 surveillance.
Financial Performance
Dhansa Labs Limited reported revenue of Rs 133.19 Cr for the most recent period. The company's EPS is Rs 2.21. Net profit for the fiscal year ending March 2025 was Rs 4.78 Cr, a decline from Rs 7.72 Cr in March 2024. Quarterly revenue for March 2026 was Rs 40.54 Cr with a net profit of Rs 2 Cr.
Profitability & Returns
The company's Return on Equity (ROE) stands at 5.59%, while Return on Capital Employed (ROCE) is 7.23%. Dhansa Labs Limited has a profit margin of 0%. The EPS for the latest period is Rs 2.21, down from Rs 4.25 in March 2024, and Rs 2.06 in March 2025.
Balance Sheet
Dhansa Labs Limited has a debt-to-equity ratio of 0.81. The book value per share is Rs 39.62. No dividend yield was reported for the company.
Ownership & Pledges
There has been a decrease in promoter holding from 70.1469% in March 2025 to 65.0455% in May 2026. No promoter shares are reported as pledged.
Regulatory & Surveillance
Dhansa Labs Limited is currently under ESM (Enhanced Surveillance Measure), specifically ESM Stage 1. This indicates heightened monitoring by regulatory authorities.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.